Happy Sunday, hope it’s an enjoyable one.
Today, I want to look at the major players for a potential COVID vaccine. I think we can ultimately break it down to 4 major players, but we’ll add some honorable mentions too.
Now too preface, it’s completely your call if you want exposure in these public companies. Them releasing a vaccine will definitely increase their stock price, but maybe not for the long-term. For example, Novavax recently released promising pre-clincial results, but their shares actually slide on the news ($NVAX). Now, I recently learned this myself, but the steps to create, if you will, a vaccine start with a pre-clinical trial. This will normally be a smaller sample size. Then a phase 1 trial, then two, then phase three is a large sample size maybe 30,000+ (and apologies if I am completely wrong on that).
Major Players – First Moderna ($MRNA) , recently receiving a 483 million dollar loan with the U.S. Government. They are way ahead of the game after going 45 for 45 in their phase 1 trials they got to skip phase 2 and go straight to phase 3. Recently, they released PRICING for their vaccine. Why would you and how could you price something if it is so far away from coming out? Well Moderna is ahead of schedule with a very promising outlook. They said they would price the vaccine between $32 to $37.
Next is Pfizer, ($PFE), who said in their earnings called they are targeting OCTOBER for their vaccine. Pfizer also received money from the Gov’t and has released pricing for their vaccine.
AstraZenca, ($AZN), came onto the game sneakily quick. They have the green light for phase 3.
Johnson and Johnson could be an underdog, ($JNJ). They have a deal with the U.S. Gov’t to produce 100 million doses. The reason JNJ is a sneaky pick is because the other three mentioned above all of to do a second boost of doses or a second round if you will. The JNJ one is just one round and could have their results a lot quicker.
Honorable mention Novavax ($NVX), BioNtech, and ($BNTX)..
Will continue to update this